Clinical Trials

Phase 2 Active not recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05063565 2026-04-29

ROWAN

100 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT05941897 2026-03-05

LOTOS

Phase 2 Active not recruiting

39 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03911557 2025-11-12

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

14 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT02938793 2025-09-23

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Phase 2 Terminated

92 enrolled

Neoplasms, Rare Diseases

NCT03847649 2025-06-11

A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies

60 enrolled

Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

61 enrolled

Neoplasms

NCT03822351 2024-10-08

COAST

189 enrolled 24 charts

GastrointestinalGenitourinaryGynecologic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Phase 2 Terminated

41 enrolled 13 charts

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT03094286 2024-06-24

Durvalumab in HIV-1 Patients With Solid Tumors

20 enrolled 36 charts

Phase 2 Active not recruiting

Neoplasms

NCT04392505 2024-02-29

DART

100 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT02904954 2023-10-11

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

60 enrolled 12 charts